| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
O'Keefe Kenneth W serves as a Director at JAZZ. Across recent SEC filings that breaks down to 3 buys and 14 sells. Those positions are worth an estimated $4.5M at current prices.
Historically, O'Keefe Kenneth W's trades have earned a middling insider score of 63/100 across 4 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +11.9%.
The biggest single holding is JAZZ (~$4.5M) as Director. The recent filings there lean toward selling, a net 25,055 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2016 | JAZZ Jazz Pharmaceuticals Plc | Director | Buy | 2,000 | $113.84 | $227,688.14 | New |